West Asia Geopolitical Tensions Trigger Raw Material Crisis for Madhya Pradesh's MSME Pharma Sector
The ongoing geopolitical tensions and military conflicts in West Asia, particularly involving Israel, Iran, and regional actors, have severely disrupted global supply chains, creating a cascading crisis for Micro, Small, and Medium Enterprise (MSME) pharmaceutical manufacturers in Madhya Pradesh. Industry representatives are issuing urgent warnings that numerous small drug manufacturing units across the state face imminent closure within the next two to three months if immediate government intervention is not forthcoming.
Severe Liquidity Pressure and Rising Production Costs
According to the MP Small and Medium Drug Manufacturing Association, the MSME pharma sector, which fulfills nearly 90 percent of medicine supplies to central and state government health corporations, is grappling with severe liquidity pressure. This critical situation stems from a dual challenge: skyrocketing input costs due to global raw material price spikes and payments from government agencies that remain stuck for months on end.
Dr. Darshan Kataria, President of the association, explained the core issue: "With rising raw material prices and delayed payments, many units are struggling to sustain day-to-day operations. The problem is compounded by our dependency on imports—approximately 75 percent of the raw materials used in drug manufacturing are sourced from overseas. The recent price surges, exacerbated by supply chain disruptions from West Asia, have sharply and unpredictably increased our production costs."
Contractual Penalties Amid Global Supply Disruptions
The crisis is further intensified by the contractual obligations MSME manufacturers face when supplying medicines under public tenders. Units are subject to penalties or even blacklisting if deliveries are delayed, regardless of whether those delays are caused by uncontrollable global supply chain disruptions, such as those currently emanating from the West Asia region.
Ajay Singh Dassundi, Secretary of the association, highlighted the impossible position manufacturers find themselves in: "Many of our members are now caught in a devastating bind between facing contractual penalties and absorbing unsustainable financial losses. The system lacks the necessary flexibility to account for these external, geopolitical shocks affecting supply timelines."
Urgent Demands and Proposed Relief Measures
In response to this escalating emergency, the association has formally submitted a set of urgent demands to both central and state government authorities. The primary objective is to stabilize the sector and prevent a collapse that would jeopardize the uninterrupted supply of essential medicines to public health programs.
The key proposals include:
- An immediate 60-day extension in supply timelines for all existing government contracts to account for global logistical delays.
- A temporary, emergency waiver of all penalties and blacklisting threats related to deliveries delayed due to the ongoing international supply chain crisis.
- The prompt release of all pending payments owed to MSME manufacturers by government health corporations to alleviate the acute liquidity crunch.
Additionally, the association has proposed the issuance of short-term, emergency tenders specifically for life-saving and essential medicines, alongside other targeted relief measures designed to support domestic manufacturers through this period of extreme volatility.
Imminent Threat of Widespread Shutdowns
Dassundi issued a stark final warning regarding the timeline of the crisis: "We are urging the government to release pending payments immediately and provide critical flexibility in supply timelines. The current situation is untenable. If no supportive measures are introduced, a large number of MSME pharmaceutical units across Madhya Pradesh may be forced to cease operations entirely within the next 60 to 90 days."
The association's appeal underscores a critical need for coordinated policy action to safeguard a vital segment of India's pharmaceutical supply chain, ensuring that domestic production of essential medicines remains secure despite turbulent international circumstances.
